GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction.
作者信息
Mocciaro Gabriele, Capodici Angelo, De Amicis Ramona
机构信息
Roger Williams Institute of Liver Studies, Foundation for Liver Research, London, UK.
Health Science Interdisciplinary Center, Sant'Anna School of Advanced Studies, 56127 Pisa, Italy, Pisa, Italy.
出版信息
BMJ Nutr Prev Health. 2025 Mar 3;8(1):e001206. doi: 10.1136/bmjnph-2025-001206. eCollection 2025.
Abstract
摘要
相似文献
1
GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction.胰高血糖素样肽-1受体激动剂会导致瘦体重减少：热量限制也会如此。
BMJ Nutr Prev Health. 2025 Mar 3;8(1):e001206. doi: 10.1136/bmjnph-2025-001206. eCollection 2025.
2
Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.抗体阻断激活素 II 型受体可在 GLP-1 受体激动剂作用下保留骨骼肌质量并促进脂肪丢失。
Mol Metab. 2024 Feb;80:101880. doi: 10.1016/j.molmet.2024.101880. Epub 2024 Jan 11.
3
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.胰高血糖素样肽-1受体激动剂和协同激动剂对身体成分的影响：系统评价与网状荟萃分析。
Metabolism. 2025 Mar;164:156113. doi: 10.1016/j.metabol.2024.156113. Epub 2024 Dec 22.
4
Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration.与安慰剂或GLP-1受体激动剂相比，替尔泊肽在肥胖或超重成人中的减肥疗效：治疗持续时间≥20周的随机对照试验的荟萃分析
J Obes. 2025 Jul 24;2025:3442754. doi: 10.1155/jobe/3442754. eCollection 2025.
5
"Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions.整形手术中的“司美格鲁肽面容”：关于胰高血糖素样肽-1受体激动剂介导体重减轻的文献系统综述及公众认知分析
Aesthet Surg J Open Forum. 2025 Jun 11;7:ojaf056. doi: 10.1093/asjof/ojaf056. eCollection 2025.
6
Preoperative optimization of obese spine patients with GLP-1 receptor agonists: enhancing surgery and improving outcomes.使用胰高血糖素样肽-1受体激动剂对肥胖脊柱患者进行术前优化：增强手术效果并改善预后。
J Spine Surg. 2025 Jun 27;11(2):339-346. doi: 10.21037/jss-24-152. Epub 2025 Apr 14.
7
The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP-1 Agonists: A Literature Review.选择性雄激素受体调节剂（SARMs）和抗肌生成抑制素药物在解决GLP-1激动剂引起的瘦体重损失方面的潜力：一项文献综述
J Diabetes. 2025 Aug;17(8):e70119. doi: 10.1111/1753-0407.70119.
8
GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies.胰高血糖素样肽-1受体激动剂、身体成分、骨骼肌与肌肉减少症风险：从动物模型中的有前景发现到人体研究中的争议性问题
Diabetes Metab. 2025 Sep;51(5):101681. doi: 10.1016/j.diabet.2025.101681. Epub 2025 Jun 24.
9
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.基于胰高血糖素样肽-1 的治疗方法和缓解策略对去脂体重的影响。
Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27. doi: 10.1111/dom.15728. Epub 2024 Jun 27.
10
Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.肥胖人群中胰高血糖素样肽-1 受体激动剂对骨骼健康影响的叙述性综述。
Calcif Tissue Int. 2024 Feb;114(2):86-97. doi: 10.1007/s00223-023-01150-8. Epub 2023 Nov 24.
本文引用的文献
1
Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps.胰高血糖素样肽-1 受体激动剂类药物与体重减轻成分：填补空白。
Diabetes Obes Metab. 2024 Dec;26(12):5503-5518. doi: 10.1111/dom.15913. Epub 2024 Sep 30.
2
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity.在使用肠促胰岛素类似物治疗肥胖症期间尽量减少肌肉流失的策略。
Obes Rev. 2025 Jan;26(1):e13841. doi: 10.1111/obr.13841. Epub 2024 Sep 19.
3
On the pathogenesis of obesity: causal models and missing pieces of the puzzle.肥胖发病机制：因果模型和未解之谜。
Nat Metab. 2024 Oct;6(10):1856-1865. doi: 10.1038/s42255-024-01106-8. Epub 2024 Aug 20.
4
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.肥胖中的胰高血糖素样肽-1生理机制及用于慢性体重管理的肠促胰岛素类药物的研发。
Nat Metab. 2024 Oct;6(10):1866-1885. doi: 10.1038/s42255-024-01113-9. Epub 2024 Aug 19.
5
Understanding the cause of type 2 diabetes.了解2型糖尿病的病因。
Lancet Diabetes Endocrinol. 2024 Sep;12(9):664-673. doi: 10.1016/S2213-8587(24)00157-8. Epub 2024 Jul 19.
6
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.基于胰高血糖素样肽-1 的治疗方法和缓解策略对去脂体重的影响。
Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27. doi: 10.1111/dom.15728. Epub 2024 Jun 27.
7
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。执行摘要。
Diabetologia. 2024 Nov;67(11):2375-2392. doi: 10.1007/s00125-024-06196-3.
8
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.运动、利拉鲁肽或两者联合用于维持健康的体重减轻。
N Engl J Med. 2021 May 6;384(18):1719-1730. doi: 10.1056/NEJMoa2028198.
9
Very low calorie ketogenic diets in overweight and obesity treatment: Effects on anthropometric parameters, body composition, satiety, lipid profile and microbiota.极低卡路里生酮饮食在超重和肥胖治疗中的应用：对人体测量参数、身体成分、饱腹感、血脂谱和微生物群的影响。
Obes Res Clin Pract. 2020 Nov-Dec;14(6):491-503. doi: 10.1016/j.orcp.2020.08.009. Epub 2020 Sep 9.
10
Exercise and metabolic health: beyond skeletal muscle.运动与代谢健康：超越骨骼肌。
Diabetologia. 2020 Aug;63(8):1464-1474. doi: 10.1007/s00125-020-05177-6. Epub 2020 Jun 11.
Zotero 插件